PharmaTimes4h
Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
PharmaTimes4h
Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol
Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for ...
PharmaTimes23h
AstraZeneca receives positive recommendations for lung cancer treatments
AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...